Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis

Alicia M Maceira, Sanjay K Prasad, Philip N Hawkins, Michael Roughton, Dudley J Pennell, Alicia M Maceira, Sanjay K Prasad, Philip N Hawkins, Michael Roughton, Dudley J Pennell

Abstract

Background: Cardiac involvement is common in amyloidosis and associated with a variably adverse outcome. We have previously shown that cardiovascular magnetic resonance (CMR) can assess deposition of amyloid protein in the myocardial interstitium. In this study we assessed the prognostic value of late gadolinium enhancement (LGE) and gadolinium kinetics in cardiac amyloidosis in a prospective longitudinal study.

Materials and methods: The pre-defined study end point was all-cause mortality. We prospectively followed a cohort of 29 patients with proven cardiac amyloidosis. All patients underwent biopsy, 2D-echocardiography and Doppler studies, 123I-SAP scintigraphy, serum NT pro BNP assay, and CMR with a T1 mapping method and late gadolinium enhancement (LGE).

Results: Patients with were followed for a median of 623 days (IQ range 221, 1436), during which 17 (58%) patients died. The presence of myocardial LGE by itself was not a significant predictor of mortality. However, death was predicted by gadolinium kinetics, with the 2 minute post-gadolinium intramyocardial T1 difference between subepicardium and subendocardium predicting mortality with 85% accuracy at a threshold value of 23 ms (the lower the difference the worse the prognosis). Intramyocardial T1 gradient was a better predictor of survival than FLC response to chemotherapy (Kaplan Meier analysis P = 0.049) or diastolic function (Kaplan-Meier analysis P = 0.205).

Conclusion: In cardiac amyloidosis, CMR provides unique information relating to risk of mortality based on gadolinium kinetics which reflects the severity of the cardiac amyloid burden.

Figures

Figure 1
Figure 1
Survival curve according to late gadolinium enhancement (LGE). The figure shows the Kaplan Meier curve of survival according to the presence or absence of late gadolinium enhancement (LGE). No differences in survival were seen with respect to this parameter.
Figure 2
Figure 2
Differences in T1 after gadolinium injection between survivors and patients who died. The figure shows the differences in T1 of blood, subendocardium and subepicardium with time after gadolinium injection between survivors and patients who died on follow-up. Patients who died on follow up showed a higher blood T1 after gadolinium injection.
Figure 3
Figure 3
Top: Intramyocardial T1 difference in survivors and patients who died. Bottom: Survival curve according to intramyocardial T1 difference. The top graph shows the intramyocardial T1 difference (subepicardium – subendocardium) with time after gadolinium injection in survivors and patients who died. Survivors showed a significantly higher intramyocardial T1 difference after gadolinium injection. The bottom image shows the Kaplan Meier curve of survival according to intramyocardial T1 difference set a threshold value of 23 ms. Patients with an intramyocardial T1 difference above 23 ms had increased survival.
Figure 4
Figure 4
Top: Subepicardium to blood T1 difference in survivors and patients who died. Bottom: Survival curve according to this T1 difference. The top graph shows the subepicardium to blood T1 difference with time after gadolinium injection in survivors and patients who died. Survivors showed a significantly higher subepicardium to blood T1 difference after gadolinium injection. The bottom figure shows the Kaplan Meier curve of survival according to subepicardium to blood T1 difference set at a threshold value of 80 ms. Patients with a subepicardium to blood T1 difference above 80 ms had a better survival.
Figure 5
Figure 5
Top: Subendocardium to blood T1 difference in survivors and those who died. Bottom: Survival curve according to this T1 difference. The top graph shows the subendocardium to blood T1 difference with time after gadolinium injection in survivors and patients who died. Survivors showed a significantly higher subendocardium to blood T1 difference after gadolinium injection. The bottom figure shows the Kaplan Meier curve of survival according to subendocardium to blood T1 difference set a threshold value of 68 ms. No significant differences in survival were seen for this parameter.
Figure 6
Figure 6
Top: Survival curve according to FLC response. Bottom: Survival curve according to diastolic function. The top graph shows the Kaplan Meier curve of survival according to free light chain response to chemotherapy. Patients with partial/complete response had better survival. The bottom image shows the Kaplan Meier curve of survival according to diastolic function. The discrimination of survivors from non-survivors was superior for gadolinium kinetics (figure 3).

References

    1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337:898–909. doi: 10.1056/NEJM199709253371306.
    1. Kyle RA, Greipp PR, O'Fallon WM. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood. 1986;68:220–4.
    1. Arbustini E, Gavazzi A, Merlini G. Fibril-forming proteins: the amyloidosis: new hopes for a disease that cardiologists must know. Ital Heart J Suppl. 2002;3(6):590–597.
    1. Nihoyannopoulos P. Amyloid heart disease. Current Opin Cardiol. 1987;2:371–6.
    1. Falk RH, Skinner M. The systemic amyloidoses: an overview. Adv Intern Med. 2000;45:107–137.
    1. Maceira AM, Joshi J, Prasad SK, Moon JCC, Perugini E, Harding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell D. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111:195–202. doi: 10.1161/01.CIR.0000152819.97857.9D.
    1. Klein AL, Hatle LK, Burstow DJ, Seward JB, Kyle RA, Bailey KR, Luscher TF, Gertz MA, Tajik AJ. Doppler characterization of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol. 1989;13:1017–1026.
    1. Moyssakis I, Tripdskiadis F, Rallidis L, Hawkins P, Kyriakidis M, Nihoyannopoulos P. Echocardiographic features of primary, secondary and familial amyloidosis. Eur J Clin Invest. 1999;29:484–489. doi: 10.1046/j.1365-2362.1999.00478.x.
    1. Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, Hawkins PN. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122:78–84. doi: 10.1046/j.1365-2141.2003.04433.x.
    1. Maceira AM, Prasad SK, Khan M, Pennell DJ. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2006;8:417–26. doi: 10.1080/10976640600572889.
    1. Sueyoshi E, Sakamoto I, Okimoto T, Hayashi K, Tanaka K, Toda G. Cardiac amyloidosis: typical imaging findings and diffuse myocardial damage demonstrated by delayed contrast-enhanced MRI. Cardiovasc Intervent Radiol. 2006;29:710–2. doi: 10.1007/s00270-004-0162-x.
    1. Cheng AS, Banning AP, Mitchell AR, Neubauer S, Selvanayagam JB. Cardiac changes in systemic amyloidosis: visualisation by magnetic resonance imaging. Int J Cardiol. 2006;113:E21–3. doi: 10.1016/j.ijcard.2006.07.107.
    1. Perugini E, Rapezzi C, Piva T, Leone O, Bacchi-Reggiani L, Riva L, Salvi F, Lovato L, Branzi A, Fattori R. Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart. 2006;92:343–9. doi: 10.1136/hrt.2005.061911.
    1. Cacoub P, Axler O, De Zuttere D, Hausfater P, Amoura Z, Walter S, Wechsler B, Godeau P, Piette JC. Amyloidosis and cardiac involvement. Ann Med Interne (Paris) 2000;151(8):611–617.
    1. Kristen AV, Perz JB, Schonland SO, Hegenbart U, Schnabel PA, Kristen JH, Goldschmidt H, Katus HA, Dengler TJ. Non-invasive predictors of survival in cardiac amyloidosis. Eur J Heart Fail. 2007;9:617–24. doi: 10.1016/j.ejheart.2007.01.012.
    1. Klein AL, Hatle LK, Taliercio CP, Oh JK, Kyle RA, Gertz MA, Bailey KR, Seward JB, Tajik AJ. Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation. 1991;83:808–16.
    1. Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, Obici L, Bradwell AR, D'Eril GM, Fogari R, Moratti R, Merlini G. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood. 2006;107:3854–8. doi: 10.1182/blood-2005-11-4385.
    1. Kholova I, Kautzner J. Current treatment in cardiac amyloidosis. Curr Treat Options Cardiovasc Med. 2006;8:468–73. doi: 10.1007/s11936-006-0035-5.
    1. Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature. 2002;417:254–9. doi: 10.1038/417254a.
    1. Dember LM, Hawkins PN, Hazenberg BP, Gorevic PD, Merlini G, Butrimiene I, Livneh A, Lesnyak O, Puechal X, Lachmann HJ, Obici L, Balshaw R, Garceau D, Hauck W, Skinner M, Eprodisate for AA Amyloidosis Trial Group Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med. 2007;356:2349–60. doi: 10.1056/NEJMoa065644.
    1. Gillmore JD, Goodman HJ, Lachmann HJ, Offer M, Wechalekar AD, Joshi J, Pepys MB, Hawkins PN. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood. 2006;107:1227–9. doi: 10.1182/blood-2005-08-3253.
    1. Maurer MS, Raina A, Hesdorffer C, Bijou R, Colombo P, Deng M, Drusin R, Haythe J, Horn E, Lee SH, Marboe C, Naka Y, Schulman L, Scully B, Shapiro P, Prager K, Radhakrishnan J, Restaino S, Mancini D. Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure. Transplantation. 2007;83:539–45. doi: 10.1097/.
    1. Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: a comprehensive review. Arch Intern Med. 2006;166:1805–13. doi: 10.1001/archinte.166.17.1805.
    1. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol. 2003;41:1561–7. doi: 10.1016/S0735-1097(03)00189-X.
    1. Assomull RG, Prasad SK, Lyne J, Smith GC, Burman ED, Khan M, Sheppard MN, Poole-Wilson PA, Pennell DJ. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1977–85. doi: 10.1016/j.jacc.2006.07.049.
    1. Tanner MA, Galanello R, Dessi C, Westwood MA, Smith GC, Nair SV, Anderson LJ, Walker JM, Pennell DJ. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson. 2006;8:543–7. doi: 10.1080/10976640600698155.
    1. Moon JC, Sheppard M, Reed E, Lee P, Elliott PM, Pennell DJ. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson. 2006;8:479–82. doi: 10.1080/10976640600605002.
    1. Anderson LJ, Holden S, Davies B, Prescott E, Charrier C, Bunce NH, Firmin DN, Porter JB, Wonke B, Walker JM, Pennell DJ. Cardiovascular T2* (T2 star) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171–9. doi: 10.1053/euhj.2001.2822.
    1. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol. 2005;79:319–28. doi: 10.1002/ajh.20381.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅